ISARIC - International Severe Acute Respiratory and Emerging Infection Consortium - is a global initiative aiming to ensure that clinical researchers have the open access protocols and data-sharing processes needed to facilitate a rapid response to emerging diseases that may turn into epidemics or pandemics.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. They have four approved products on the market today and they are not stopping there! From the United States to Europe to the Asia Pacific, they are proud of their multicultural business environment where employees can collaborate with people all over the world. As a group, they are relentless in their pursuit of “medicines for life”® and continue their research into treatments for pulmonary arterial hypertension, cancer, and some of the world’s most complicated viral illnesses.

G.D. Searle, LLC is a wholly owned trademark of Pfizer. It is currently used mainly as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Prior to its 1985 merger with Monsanto, Searle was a company focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

Emergent Virology LLC engages in glyco-biologic research services. The firm develops potential oral treatment for dengue and influenza infections. The company is headquartered in Washington, DC.

Oxford has an introduction of an e-commerce business and also the launch and development of brand licensing programs for both the belted and shield trademarks. Oxford is a subsidiary company, wholly owned by the university of oxford. They are responsible for registration, protection, and management of the university's brand, and they use this to license the use of the brand, in a wide variety of commercial categories, globally.

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.

Summit Co., Ltd. is a company headquartered in the South Korea that manufactures electrical measuring, testing and analysis instruments. It was founded in 2007.

The Monsanto Company (/mɒnˈsæntoʊ/) was an American agrochemical and agricultural biotechnology corporation founded in 1901. In 2018, it was acquired by Bayer as part of its crop science division. It was headquartered in Creve Coeur, Missouri. Monsanto developed Roundup, a glyphosate-based herbicide, in the 1970s, and became a major producer of genetically engineered crops.

The Academic Medical Center (Dutch: Academisch Medisch Centrum), or AMC, is the university hospital affiliated with the Universiteit van Amsterdam (University of Amsterdam). It is one of the largest and leading hospitals of The Netherlands, located in the Bijlmer neighborhood in the most south-eastern part of the city. AMC consistently ranks among the top 50 medical schools in the world.

Part of Emergent BioSolutions, Inc., Emergent Product Development Gaithersburg, Inc. is an American company involved in pharmaceutical preparations.

Dipharma is a European manufacturer of Active Pharmaceutical Ingredients that has been developing innovative and proprietary processes since 1949. We support our customers worldwide with a strong and well resourced R&D team, three cGMP facilities in Europe, and offer world-renowned expertise in handling hazardous chemical processes. Our customers can benefit from our broad portfolio of generic Active Pharmaceutical Ingredients and a wide range of advanced technologies available for custom synthesis. They can rely on the highest quality standards, but it does not stop there, they can count on our experience in innovation.

Botanic Century (Beijing) Co. Ltd. is a private company headquartered in Beijing, China. The firm develops and manufactures pharmaceutical drugs.

Shenzhen Qianhai Nobel Prize Scientist Technology Transfer Co., Ltd., established on 2018-12-03, Business scope includes general business items:Carrying out the Nobel Prize,Applied research on the academic achievements of scientists such as the Turing Award;nobel prize,Technology research and development in related research fields for scientists such as the Turing Award,technology transfer,Incubation;Agricultural Technology,Biotechnology,new material technology,Technical consultation on energy-saving technologies,technology R & D,Technology Promotion,Technical Services,technology transfer;High-tech technology development;R&D and transfer of scientific and technological achievements;Venture Capital;Conference Services;in the advertising business(law,Administrative regulations,The decision of the State Council stipulates that it is necessary to separately handle the examination and approval of advertising business projects,Licensed to operate);Business Consulting,Economic Information Consulting,Investment Advisory,Business Management Consulting,Educational information consultation(None of the above items are restricted);Technical development of biological products;Technology development of biotechnology products;Domestic Trade(Does not contain franchise,Exclusive control,Monopoly).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments);Sales of Class I Medical Devices;Class I Medical Device Leasing;business training(Does not include education and training,Vocational skills training and other licensed training);Information system operation and maintenance services;Network technology service;software development;software sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license),The licensing program is:Sales of Class II Medical Devices;Class III medical device business;Class III Medical Device Leasing;Class II Medical Device Leasing;Small and mini bus rental business service;Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Universiteit Utrecht Holding BV provides portfolio management and commercial development services. It strengthen and broaden cooperation among partners encompassing companies, governmental institutions, cultural and social organizations. The company was founded in 1996 and is headquartered in Utrecht, the Netherlands.

Livinguard AG is a private company headquartered in Cham, Switzerland, that operates a hygiene technology company which sells surgical and protective masks. It was founded in 2010 by Sanjeev Swamy, he has been the CEO since the inception date.\nThe company says this about itself: Livinguard is an environmentally friendly hygiene technology platform based in Cham, Switzerland. The company empowers textiles and other materials with self-disinfecting properties; it licenses its patented technologies to companies from various industries to improve the health and wellbeing of consumers. Livinguard AG operates in Switzerland, Germany, USA, Singapore, Japan, India, and South Africa. Livinguard is a member of the World Economic Forum?s Innovators Community. The company sees its solutions as essential safeguards that can offer enhanced hygiene and sustainability to billions of people.

Dorphan S.A. was founded in 2011 by the members of the Swiss Sanfilippo Foundation in order to discover and pursue the development of drug candidates for orphan and rare genetic diseases. The company R&D activities are built on worldwide innovative research to identify, evaluate and develop preclinical molecules and deliver promising drug candidates to patients.

ICCAS was founded in 1956. ICCAS is a multi-disciplinary research institute dedicated to the basic research in broad fields of chemical sciences, and to the key developments of the innovative high technologies aiming to the imperative national needs and important strategic targets, as well as to the collaborative high-technology applications and transfers. ICCAS is one of China’s leading chemistry research institutions with high international reputation.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

Actelion Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of low molecular weight drugs for various medical needs. Its principal products include Tracleer, an orally available dual endothelin receptor antagonist, approved as a therapy for pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart; and Zavesca, in-licensed from Oxford GlycoSciences, an oral medication indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. The company also offers Ventavis, an inhaled synthetic analogue of prostacyclin that produces potent pulmonary vasodilation and inhibits platelet aggregation. In addition, Actelion evaluates various compounds in various phases of clinical development for treating cardiovascular, cardiopulmonary, immunological, and infectious diseases, as well as metabolic and central nervous system disorders. In addition, it has an exclusive worldwide alliance with Merck & Co, Inc. to discover, develop, and market new classes of renin inhibitors for patients suffering from cardio-renal diseases. Actelion markets Tracleer in the United States, the European Union, Japan, Canada, Australia, and Switzerland. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.